Latest News-Harbour Biomed Mediaroom_Page

Nona Biosciences Integrates Cutting-Edge AI Technology to Enhance Its Fully Human Antibody Platform, Accelerating Antibody Discovery Across Key Therapeutic Areas

CAMBRIDGE, Mass., March 7, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company pr...

2025-03-07 14:00 2130

HBM Alpha Therapeutics Enters Strategic Collaboration and License Agreement to Advance Novel Endocrine Therapies

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI , Feb. 25, 2025 /PRNewswire/ -- HBM Alpha The...

2025-02-26 08:03 2449

Harbour BioMed and Insilico Medicine Achieve Strategic Collaboration to Advance AI-Driven Antibody Discovery and Development

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Feb. 20, 2025 /PRNewswire/ -- Harbour BioMed...

2025-02-20 15:31 2813

Nona Biosciences Announces Licensing Agreement with the University of Alabama at Birmingham to Support B Cell Development Research

CAMBRIDGE, Mass., Feb. 19, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company pr...

2025-02-20 09:21 2420

Harbour BioMed Announces Business Progress and Update

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Feb. 13, 2025 /PRNewswire/ -- Harbour BioMed...

2025-02-14 12:08 4183

Harbour BioMed Receives NMPA IND Clearance for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Feb. 4, 2025 /PRNewswire/ -- Harbour BioMed ...

2025-02-05 12:28 2896

Nona Biosciences Announces Strategic Collaboration with Invetx for Next-Generation Animal Health Biotherapeutics Discovery

CAMBRIDGE, Mass., Feb. 3, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company pro...

2025-02-03 20:00 2689

Harbour BioMed Announces License Agreement with Windward Bio for HBM9378/SKB378, an Anti-TSLP Fully Human Antibody for Immunological Diseases

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 10, 2025 /PRNewswire/ -- Harbour BioMed...

2025-01-10 21:01 5141

Nona Biosciences Announces Update on Its Collaborator DualityBio's Antibody-Drug Conjugate (ADC) Collaboration with BeiGene

CAMBRIDGE, Mass., Jan. 3, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company pro...

2025-01-03 13:30 2639

Nona Biosciences Announces Discovery Collaboration with Candid Therapeutics for Next-Generation T-Cell Engagers

CAMBRIDGE, Mass., Dec. 16, 2024 /PRNewswire/ -- Nona Biosciences, a global biotechnology company pr...

2024-12-16 20:03 1741

Nona Biosciences and Kodiak Sciences Partner on Next-Generation Antibody Therapies for Ophthalmic Diseases

CAMBRIDGE, Mass., Dec. 9, 2024 /PRNewswire/ -- Nona Biosciences, a global biotechnology company pro...

2024-12-10 10:18 2253

Harbour BioMed Appoints Dr. Raymond Zheng as Chief Business Officer

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Nov. 14, 2024 /PRNewswire/ -- Harbour B...

2024-11-15 09:55 2474

Harbour BioMed Announces Submission of IND Application for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Nov. 8, 2024 /PRNewswire/ -- Harbour Bi...

2024-11-08 17:45 2148

Harbour BioMed Announces Publication of the Phase I Study Results for Porustobart in Combination with Toripalimab in Advanced Melanoma and Other Solid Tumors

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Oct. 9, 2024 /PRNewswire/ -- Harbour Bi...

2024-10-10 11:04 2496

Nona Biosciences Enters Strategic Collaboration with OverT Bio to Advance Next-Generation Cell Therapies for Solid Tumors

CAMBRIDGE, Mass., Oct. 9, 2024 /PRNewswire/ -- Nona Biosciences, a global biotechnology company pro...

2024-10-09 20:00 2184

Nona Biosciences Enters Strategic Collaboration with Alkyon Therapeutics for Next-Generation Immunotherapeutics Discovery

CAMBRIDGE, Mass., Sept. 24, 2024 /PRNewswire/ -- Nona Biosciences, a global biotechnology company p...

2024-09-24 20:00 1675

Harbour BioMed Announces the Latest Clinical Data on the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Sept. 14, 2024 /PRNewswire/ -- Harbour ...

2024-09-14 16:06 4767

Nona Biosciences Enters into Collaboration Agreement with Umoja Biopharma to Advance In Vivo CAR-T Cell Therapies

CAMBRIDGE, Mass., Sept. 12, 2024 /PRNewswire/ -- Nona Biosciences, a global biotechnology company p...

2024-09-13 09:27 2363

Harbour BioMed Announces 2024 Interim Results

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Aug. 28, 2024 /PRNewswire/ -- Harbour B...

2024-08-28 17:44 2972

Harbour BioMed to Present the Latest Progress of the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China , July 25, 2024 /PRNewswire/ -- Harbour ...

2024-07-26 10:16 2625